{
    "id": 3692,
    "fullName": "KRAS G13R",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KRAS G13R is a hotspot mutation that lies within a GTP-binding region of the Kras protein (UniProt.org, PMID: 23455880). G13R has been identified in the scientific literature (PMID: 23196793, PMID: 22753589, PMID: 28508873), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 16544,
                    "pubMedId": 28508873,
                    "title": "Mutant KRAS promotes malignant pleural effusion formation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28508873"
                },
                {
                    "id": 12268,
                    "pubMedId": 23196793,
                    "title": "Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23196793"
                },
                {
                    "id": 26,
                    "pubMedId": 23455880,
                    "title": "KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23455880"
                },
                {
                    "id": 8014,
                    "pubMedId": 22753589,
                    "title": "Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22753589"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3845,
        "geneSymbol": "KRAS",
        "terms": [
            "KRAS",
            "'C-K-RAS",
            "C-K-RAS",
            "c-Ki-ras",
            "c-Ki-ras2",
            "CFC2",
            "K-Ras",
            "K-Ras 2",
            "K-RAS2A",
            "K-RAS2B",
            "K-RAS4A",
            "K-RAS4B",
            "KI-RAS",
            "KRAS1",
            "KRAS2",
            "NS",
            "NS3",
            "OES",
            "RALD",
            "RASK2"
        ]
    },
    "variant": "G13R",
    "createDate": "03/12/2015",
    "updateDate": "10/22/2019",
    "referenceTranscriptCoordinates": {
        "id": 157160,
        "transcript": "NM_033360",
        "gDna": "chr12:g.25245348C>G",
        "cDna": "c.37G>C",
        "protein": "p.G13R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7865,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 26080,
                "profileName": "HRAS G12R KRAS G13R"
            },
            "therapy": {
                "id": 4600,
                "therapyName": "Dasatinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7854,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture and in cell line xenograft models (PMID: 27222538).",
            "molecularProfile": {
                "id": 26080,
                "profileName": "HRAS G12R KRAS G13R"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7866,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 26080,
                "profileName": "HRAS G12R KRAS G13R"
            },
            "therapy": {
                "id": 4601,
                "therapyName": "Dasatinib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7858,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 26080,
                "profileName": "HRAS G12R KRAS G13R"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7864,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 26080,
                "profileName": "HRAS G12R KRAS G13R"
            },
            "therapy": {
                "id": 4599,
                "therapyName": "Dasatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3496,
            "profileName": "KRAS G13R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26080,
            "profileName": "HRAS G12R KRAS G13R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 157160,
            "transcript": "NM_033360",
            "gDna": "chr12:g.25245348C>G",
            "cDna": "c.37G>C",
            "protein": "p.G13R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157159,
            "transcript": "NM_004985",
            "gDna": "chr12:g.25245348C>G",
            "cDna": "c.37G>C",
            "protein": "p.G13R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157162,
            "transcript": "XM_011520653",
            "gDna": "chr12:g.25245348C>G",
            "cDna": "c.37G>C",
            "protein": "p.G13R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157163,
            "transcript": "XM_006719069",
            "gDna": "chr12:g.25245348C>G",
            "cDna": "c.37G>C",
            "protein": "p.G13R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157161,
            "transcript": "XM_017019293",
            "gDna": "chr12:g.25245348C>G",
            "cDna": "c.37G>C",
            "protein": "p.G13R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}